Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000483475 | SCV000570609 | uncertain significance | not provided | 2016-06-10 | criteria provided, single submitter | clinical testing | This variant is denoted PMS2 c.1450C>T at the cDNA level, p.Pro484Ser (P484S) at the protein level, and results in the change of a Proline to a Serine (CCT>TCT). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. PMS2 Pro484Ser was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Proline and Serine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. PMS2 Pro484Ser occurs at a position that is not conserved and is not located in a known functional domain (Guarne 2001, Fukui 2011). In silico analyses predict that this variant is unlikely to alter protein structure or function. Based on currently available evidence, it is unclear whether PMS2 Pro484Ser is pathogenic or benign. We consider it to be a variant of uncertain significance. |
Ambry Genetics | RCV002395164 | SCV002696863 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-01-16 | criteria provided, single submitter | clinical testing | The p.P484S variant (also known as c.1450C>T), located in coding exon 11 of the PMS2 gene, results from a C to T substitution at nucleotide position 1450. The proline at codon 484 is replaced by serine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |